Provisional patent applications have taken on increased significance in recent years and can be a savvy business move and help inventors stake a claim to an invention, but if not done right, provisionals can leave applicants with no protections or, worse yet, undermine their patents down the road.
Nearly 20 technology companies have joined forces to pool their patents into a licensing consortium designed to promote an emerging wireless tracking technology that could one day replace bar codes on packaged goods.
Merchant bank Ocean Tomo has launched an investment fund to provide private equity capital and mezzanine debt to companies with undervalued intellectual property rights, including patents and trademarks.
King Pharmaceuticals has sued Israel’s Teva Pharmaceuticals in federal courts in Delaware and New Jersey over Teva’s plans to make a generic version of the line of insomnia drugs marketed under the label Sonata.
Canadian drug maker Apotex Inc. has sued Merck & Co. for damages for lost sales of a generic version of osteoporosis drug Fosamax.
Kevin Goering, a seasoned media litigator with extensive experience in intellectual property, has left Coudert Brothers in New York to join Sheppard, Mullin, Richter & Hampton LLP as a partner in the Business Trial Practice Group.
In a legal assault that targets large swaths of the travel and financial-services industries, a small California company has filed a patent infringement lawsuit against travel-services giant Cendant Corp. over a widely used business method.
A pair of decisions by a federal appeals court has left communications equipment maker Harris Corp. bruised, if not defeated, in a 17-year battle with Swedish rival Ericsson, Inc. over wireless gear patents.
Patents granted by the U.K. Patent Office rose 8% in 2004, fuelled largely by patenting by technology companies, the government agency said.
A federal judge in Manhattan has ruled for “Da Vinci Code” author Dan Brown in a $150 million copyright infringement lawsuit filed by an author who claimed the best-selling thriller plagiarized his novel.
Symbol Technologies Inc., a maker of bar code scanners and handheld computers, said Friday that it settled its trademark, trade-dress and design-patent lawsuit against Mobile Knowledge Group Services Inc.
In a setback for Nokia, the U.S. Court of Appeals for the Federal Circuit has barred the Finnish mobile handset maker from intervening in a patent suit between competitor Ericsson, Inc. and cellular technology vendor InterDigital Communications.
An obscure Scottish company that had filed a mysterious challenge to the U.K. patent covering Sanofi-Aventis’ best-selling blood thinner Plavix has dropped its lawsuit, Sanofi-Aventis said Friday.
BlackBerry maker Research in Motion, Inc. is considering an appeal to the Supreme Court of the Federal Circuit’s latest decision in its drawn-out and acrimonious dispute with NTP Inc.
Japanese electronics maker NEC Corp. has settled a lawsuit against wireless network gear maker Harris Corp. over patents for mobile communications technology.
Software developer Trading Technologies pushed through additional settlement deals Thursday, bringing two competitors to the bargaining table just days after filing patent infringement suits in the Northern District of Illinois.
A patent dispute pitting big-screen movie pioneer Imax Corp. against a boutique technology vendor is raising questions about the ownership of the next generation of film technology.
International Business Machines has sold a portfolio of 250 patents for DVD-related technologies to Japanese electronics giant Mitsubishi Electric Corp., the company confirmed Wednesday.
Dewey Ballantine has hired Noemi "Nicky" Espinosa as a partner in its intellectual property group, in a move designed to bolster its presence in the emerging pharmacogenomics industry.
Japanese electronics maker Matsushita Electric Industrial Co. has sued Taiwanese chip maker MediaTek Inc in federal court in California for patent infringement related to integrated circuit chips.
Biotech companies Genentech, Inc. and Chiron have quietly settled the remaining patent disputes in a $300 million lawsuit over Genentech's metastatic breast cancer drug, Herceptin (Trastuzumab).